BIOGEN INC.
BIIBAPI behind this page
BIIB Q4 2025 request
Playground key active
/api/financials?ticker=BIIB&year=2025&quarter=4
Pick an endpoint and run the request.Income Statement
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Revenue | 2,279.4 | 2,454.7 | -7.1% |
Show Product Lines breakouts |
|||
| Alzheimer's collaboration revenue | 47.1 | 26.7 | +76.4% |
| AVONEX | 162.5 | 170 | -4.4% |
| AVONEX · Non Us | 43.3 | 62.7 | -30.9% |
| AVONEX · US | 119.2 | 107.3 | +11.1% |
| BENEPALI | 107.9 | 125 | -13.7% |
| BENEPALI · Non Us | 107.9 | 125 | -13.7% |
| BYOOVIZ | 7.9 | 9.3 | -15.1% |
| BYOOVIZ · Non Us | 3.6 | 4.4 | -18.2% |
| BYOOVIZ · US | 4.3 | 4.9 | -12.2% |
| Completed technology for SKYCLARYS (U.S.) | 133.4 | 102.2 | +30.5% |
| Completed technology for SKYCLARYS (U.S.) · Non Us | 44.5 | 31.5 | +41.3% |
| Completed technology for SKYCLARYS (U.S.) · US | 88.9 | 70.7 | +25.7% |
| Contract manufacturing revenue | 30.6 | 118 | -74.1% |
| FAMPYRA(1) | 1.1 | 14.4 | -92.4% |
| FAMPYRA(1) · Non Us | 1.1 | 14.4 | -92.4% |
| FLIXABI | 9.9 | 16.1 | -38.5% |
| FLIXABI · Non Us | 9.9 | 16.1 | -38.5% |
| FUMADERM And ADUHELM | 0 | 2.7 | -100.0% |
| FUMADERM And ADUHELM · Non Us | 0 | 1.9 | -100.0% |
| FUMADERM And ADUHELM · US | 0 | 0.8 | -100.0% |
| IMRALDI | 43.5 | 51 | -14.7% |
| IMRALDI · Non Us | 43.5 | 51 | -14.7% |
| PLEGRIDY | 63.2 | 66 | -4.2% |
| PLEGRIDY · Non Us | 38.5 | 39.3 | -2.0% |
| PLEGRIDY · US | 24.7 | 26.7 | -7.5% |
| Product | 1,667.3 | 1,832.6 | -9.0% |
| Product · Non Us | 749.6 | 1,001.1 | -25.1% |
| Product · US | 917.7 | 831.5 | +10.4% |
| QALSODY | 25 | 11.7 | +113.7% |
| QALSODY · Non Us | 17.2 | 5.3 | +224.5% |
| QALSODY · US | 7.8 | 6.4 | +21.9% |
| Royalty | 13.2 | 12.2 | +8.2% |
| Royalty revenue on sales of OCREVUS | 385.9 | 353.7 | +9.1% |
| SPINRAZA | 356.2 | 421.4 | -15.5% |
| SPINRAZA · Non Us | 187.6 | 254.6 | -26.3% |
| SPINRAZA · US | 168.6 | 166.8 | +1.1% |
| Subtotal: Biosimilars | 169.8 | 201.5 | -15.7% |
| Subtotal: Biosimilars · Non Us | 164.9 | 196.5 | -16.1% |
| Subtotal: Biosimilars · US | 4.9 | 5 | -2.0% |
| Subtotal: Multiple Sclerosis | 917.2 | 1,070.2 | -14.3% |
| Subtotal: Multiple Sclerosis · Non Us | 335.4 | 511.3 | -34.4% |
| Subtotal: Multiple Sclerosis · US | 581.8 | 558.9 | +4.1% |
| Subtotal: Rare Disease | 514.6 | 535.3 | -3.9% |
| Subtotal: Rare Disease · Non Us | 249.3 | 291.4 | -14.4% |
| Subtotal: Rare Disease · US | 265.3 | 243.9 | +8.8% |
| TECFIDERA | 111.8 | 227.8 | -50.9% |
| TECFIDERA · Non Us | 74.9 | 186.5 | -59.8% |
| TECFIDERA · US | 36.9 | 41.3 | -10.7% |
| TOFIDENCE | 0.6 | 0.1 | +500.0% |
| TOFIDENCE · US | 0.6 | 0.1 | +500.0% |
| Total Fumarate | 292.9 | 404.4 | -27.6% |
| Total Fumarate · Non Us | 99.5 | 209.5 | -52.5% |
| Total Fumarate · US | 193.4 | 194.9 | -0.8% |
| Total Interferon | 225.7 | 236 | -4.4% |
| Total Interferon · Non Us | 81.8 | 102 | -19.8% |
| Total Interferon · US | 143.9 | 134 | +7.4% |
| TYSABRI | 397.5 | 415.4 | -4.3% |
| TYSABRI · Non Us | 153 | 185.4 | -17.5% |
| TYSABRI · US | 244.5 | 230 | +6.3% |
| VUMERITY | 181.1 | 176.6 | +2.5% |
| VUMERITY · Non Us | 24.6 | 23 | +7.0% |
| VUMERITY · US | 156.5 | 153.6 | +1.9% |
| ZURZUVAE | 65.7 | 22.9 | +186.9% |
| ZURZUVAE · US | 65.7 | 22.9 | +186.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,279.4 | 2,454.7 | -7.1% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -31.3 | 15.2 | -305.9% |
Show — breakouts |
|||
| Revenue | 66.6 | 49.3 | +35.1% |
| Revenue | 64 | 18.1 | +253.6% |
| Revenue | -129.8 | -49.4 | -162.8% |
| Revenue | 521.2 | 465.2 | +12.0% |
| Revenue | -1,337.6 | -1,284.1 | -4.2% |
| Revenue | -1,256 | -1,209 | -3.9% |
| Revenue | 436 | 388.9 | +12.1% |
| Revenue | 521.2 | 465.2 | +12.0% |
| Revenue | 1,740.1 | 2,114.6 | -17.7% |
| Revenue | 296.3 | 425.3 | -30.3% |
| Revenue | 721.5 | 898.7 | -19.7% |
| Revenue | 3,416.4 | 3,180.4 | +7.4% |
| Revenue | 287.6 | 310 | -7.2% |
| Revenue | 6,987.9 | 7,156.6 | -2.4% |
| Cost of Revenue | 495.5 | 583.5 | -15.1% |
Show Product Lines breakouts |
|||
| Product · Reportable Segment | 326 | 399.9 | -18.5% |
| Royalty · Reportable Segment | 169.5 | 183.6 | -7.7% |
| Research And Development Expense Excluding Acquired In Process Cost | 509.4 | 513.3 | -0.8% |
Show Business Segments breakouts |
|||
| Reportable Segment · Early stage programs | 73.5 | 71.8 | +2.4% |
| Reportable Segment · Late stage programs | 77.6 | 74.1 | +4.7% |
| Reportable Segment · Marketed products | 127.9 | 120.6 | +6.1% |
| Reportable Segment · Research and discovery | 51.3 | 59.9 | -14.4% |
| Reportable Segment · Service Other | 179.1 | 186.9 | -4.2% |
| Selling, General & Administrative | 682.5 | 680 | +0.4% |
| Amortization And Impairment Of Acquired Intangible Assets | 136.6 | 151.2 | -9.7% |
| Restructuring Charges | 6.6 | 5.3 | +24.5% |
Show Income Statement Location breakouts |
|||
| Research And Development Expense · 2023 Cost Saving Initiatives | 3.2 | 1.1 | +190.9% |
| Research And Development Expense · Reata Integration | 4.2 | 3 | +40.0% |
| Restructuring Charges · 2023 Cost Saving Initiatives | 7.1 | 4 | +77.5% |
| Restructuring Charges · Reata Integration | -0.5 | 0.2 | -350.0% |
| Selling General And Administrative Expenses · 2023 Cost Saving Initiatives | 1.4 | 1.3 | +7.7% |
| Selling General And Administrative Expenses · Reata Integration | 1.6 | 1.4 | +14.3% |
Show Restructuring Plan breakouts |
|||
| 2023 Cost Saving Initiatives | 11.7 | 6.4 | +82.8% |
| Reata Integration | 5.3 | 4.6 | +15.2% |
| Total Costs & Expenses | 2,335.4 | 2,163.2 | +8.0% |
| Income Before Taxes | -56 | 291.5 | -119.2% |
| Income Tax Expense (Benefit) | -7.1 | 24.8 | -128.6% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 2.6 | -1.2 | +316.7% |
| Net Income | -48.9 | 266.7 | -118.3% |
Show Equity Components breakouts |
|||
| Retained Earnings | -48.9 | 266.7 | -118.3% |
Show Business Acquisition breakouts |
|||
| Reata Pharmaceuticals, Inc · Fair Value Adjustment To Inventory | 75.4 | 44.9 | +67.9% |
| Net Income | -48.9 | 266.7 | -118.3% |
Show Business Segments breakouts |
|||
| Reportable Segment | -48.9 | 266.7 | -118.3% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -21.4 | 9.4 | -327.7% |
| EPS (Basic) | -0.33 | 1.83 | -118.0% |
| EPS (Diluted) | -0.35 | 1.83 | -119.1% |
| Wtd Avg Shares (Basic) | 0.1 | 0.1 | 0.0% |
| Wtd Avg Shares (Diluted) | 0.3 | -0.1 | +400.0% |
| Operating Expenses (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -7.3 | 4.4 | -265.9% |
| Interest Income | -37.2 | -18.5 | -101.1% |
| Other Non-Operating Income (Expense) | -36.7 | 8 | -558.8% |
| Comprehensive Income | -16.1 | 276.2 | -105.8% |
| Other Comprehensive Income | 32.8 | 9.5 | +245.3% |
| Foreign Currency Transaction Gain Loss Before Tax | 45.5 | 56.5 | -19.5% |
| Interest Expense | 67.5 | 60 | +12.5% |
Balance Sheet
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,008.5 | 2,375 | +26.7% |
| Available For Sale Securities Debt Securities Current | 807.2 | — | — |
| Accounts Receivable | 1,342.4 | 1,404.8 | -4.4% |
| Due From Unconsolidated Joint Business | 524.6 | 464 | +13.1% |
| Inventory | 2,168.1 | 2,460.5 | -11.9% |
| Other Assets Current | 1,123.3 | 752.5 | +49.3% |
| Total Current Assets | 8,974.1 | 7,456.8 | +20.3% |
| Non-Current Assets | |||
| Available For Sale Securities Debt Securities Noncurrent | 431.9 | — | — |
| Property, Plant & Equipment | 3,055.4 | 3,181.3 | -4.0% |
| Operating Lease Right-of-Use Assets | 265.4 | 356.4 | -25.5% |
| Goodwill | 6,491.1 | 6,478.9 | +0.2% |
Show Business Acquisition breakouts |
|||
| Reata Pharmaceuticals, Inc | 469.2 | — | — |
| Deferred Tax Assets | 292.5 | 324.2 | -9.8% |
| Other Non-Current Assets | 750.6 | 560.5 | +33.9% |
| Total Assets | 29,439.5 | 28,049.3 | +5.0% |
| Intangible Assets | 7,379.5 | 7,884.3 | -6.4% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 9,178.5 | 9,691.2 | -5.3% |
| Current Liabilities | |||
| Taxes Payable Current | 114.8 | 548.3 | -79.1% |
| Accounts Payable | 432 | 424.2 | +1.8% |
| Other Liabilities Current | 2,802.6 | 2,807.7 | -0.2% |
| Total Current Liabilities | 3,349.4 | 5,528.8 | -39.4% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 507.6 | 190.5 | +166.5% |
| Operating Lease Liabilities | 290.4 | 334.5 | -13.2% |
| Other Non-Current Liabilities | 748.5 | 732.3 | +2.2% |
| Total Liabilities | 11,182.7 | 11,333.3 | -1.3% |
| Long-Term Debt | 6,286.8 | — | — |
| Accrued Income Taxes Noncurrent | 166.4 | 156.7 | +6.2% |
| Other Liabilities | |||
| Long Term Notes Payable | 6,286.8 | 4,547.2 | +38.3% |
Show Debt Instrument breakouts |
|||
| 2.250% Senior Notes due May 1, 2030 · Senior Notes | 1,495.7 | 1,494.7 | +0.1% |
| 3.150% Senior Notes due May 1, 2050 · Senior Notes | 1,475.6 | 1,475 | 0.0% |
| 3.250% Senior Notes due February 15, 2051 · Senior Notes | 480.3 | 476.4 | +0.8% |
| 5.050% Senior Notes due January 15, 2031 · Senior Notes | 398 | — | — |
| 5.200% Senior Notes due September 15, 2045 · Senior Notes | 1,101.5 | 1,101.1 | 0.0% |
| 5.750% Senior Notes due May 15, 2035 · Senior Notes | 645.5 | — | — |
| 6.450% Senior Notes due May 15, 2055 · Senior Notes | 690.2 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Senior Notes | 6,286.8 | 4,547.2 | +38.3% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 0.1 | 0.1 | 0.0% |
| Additional Paid-In Capital | 863.1 | 569.4 | +51.6% |
| Accumulated Other Comprehensive Income | -182 | -136.2 | -33.6% |
| Retained Earnings | 20,552.7 | 19,259.8 | +6.7% |
| Treasury Stock Value | -2,977.1 | -2,977.1 | 0.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18,256.8 | 16,716 | +9.2% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -182 | -136.2 | -33.6% |
| Additional Paid In Capital | 863.1 | 569.4 | +51.6% |
| Common Stock | 0.1 | 0.1 | 0.0% |
| Retained Earnings | 20,552.7 | 19,259.8 | +6.7% |
| Treasury Stock Common | -2,977.1 | -2,977.1 | 0.0% |
| Total Liabilities & Equity | 29,439.5 | 28,049.3 | +5.0% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -9.4 | -16.6 | +43.4% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -58.9 | 51.6 | -214.1% |
| Accumulated Net Unrealized Investment Gain Loss | 0.2 | — | — |
| Accumulated Other Comprehensive Income | -182 | -136.2 | -33.6% |
| Accumulated Translation Adjustment | -113.9 | -171.2 | +33.5% |
Cash Flow Statement
| Metric | YTD Q4 2025 | YTD Q4 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 200.2 | 184 | +8.8% |
| Inventory Write Down | 15.3 | 33.2 | -53.9% |
| Amortization Of Inventory Step Up | 75.4 | 44.9 | +67.9% |
| Stock-Based Compensation | 59.6 | 75.1 | -20.6% |
| Deferred Income Taxes | 166.9 | -58.4 | +385.8% |
| Increase Decrease In Equity Securities Fv Ni | -14.4 | 78.7 | -118.3% |
| Other Non-Cash Items | 19 | 64.5 | -70.5% |
| Increase Decrease In Other Operating Capital Net | 119.3 | 37.6 | +217.3% |
| Change in Inventory | -29.4 | -66.4 | +55.7% |
| Increase Decrease In Accrued Liabilities | 203.8 | 108.8 | +87.3% |
| Increase Decrease In Accrued Income Taxes Payable | -194 | 16.4 | -1282.9% |
| Net Cash from Operations | 511.9 | 760.9 | -32.7% |
| Investing Activities | |||
| Capital Expenditures | -43.9 | -39.3 | -11.7% |
| Payments To Acquire Intangible Assets | -16.3 | -27 | +39.6% |
| Other Investing Activities | 22.7 | -0.3 | +7666.7% |
| Net Cash from Investing | -1,231.7 | -18.6 | -6522.0% |
| Financing Activities | |||
| Tax Withholding for Share Compensation | 3 | 3.5 | -14.3% |
| Repayments Of Long Term Debt | 0 | 0 | — |
| Proceeds From Payments For Other Financing Activities | -1.3 | 4.4 | -129.5% |
| Net Cash from Financing | -137 | 7.9 | -1834.2% |
| Other Cash Flow | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -856.8 | 750.2 | -214.2% |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2.5 | -74.4 | +103.4% |
Values in millions USD. Source: SEC EDGAR 10-K filing.